BioAtla (NASDAQ:BCAB – Get Free Report) had its price target cut by equities research analysts at HC Wainwright from $17.00 to $10.00 in a report issued on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock.
A number of other equities analysts have also issued reports on the company. JPMorgan Chase & Co. reduced their target price on BioAtla from $17.00 to $14.00 and set an “overweight” rating for the company in a research note on Monday, September 25th. JMP Securities restated a “market outperform” rating and set a $12.00 target price on shares of BioAtla in a research report on Wednesday, August 2nd. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $14.80.
BioAtla Trading Down 6.3 %
Institutional Investors Weigh In On BioAtla
Several institutional investors have recently bought and sold shares of BCAB. Barclays PLC purchased a new position in BioAtla in the 2nd quarter worth approximately $27,000. Virtu Financial LLC acquired a new position in shares of BioAtla in the first quarter worth $28,000. Tower Research Capital LLC TRC grew its stake in shares of BioAtla by 71.6% in the first quarter. Tower Research Capital LLC TRC now owns 11,295 shares of the company’s stock worth $30,000 after acquiring an additional 4,711 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of BioAtla in the third quarter worth $37,000. Finally, State Board of Administration of Florida Retirement System acquired a new position in shares of BioAtla during the second quarter worth $38,000. 71.67% of the stock is currently owned by institutional investors and hedge funds.
BioAtla, Inc, a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer.
- Five stocks we like better than BioAtla
- What is the S&P/TSX Index?
- Investing in large cap stocks: Diving into big caps
- Upcoming IPO Stock Lockup Period, Explained
- Why you can make Vertex Pharmaceuticals a buy on any pullback
- What is the Dogs of the Dow Strategy? Overview and Examples
- Occidental Petroleum: Another bounce from the buy zone
Receive News & Ratings for BioAtla Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAtla and related companies with MarketBeat.com's FREE daily email newsletter.